An interventional study of High-fibre plant-based snack bar and Control snack bars in Healthy Participants, Healthy Adult Subject and Healthy Subjects, sponsored by Zoe Global Limited. Recruiting at 1 site in United Kingdom. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Zoe Global Limited · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn how eating different snack foods affects long term hunger and gut health in healthy adults. The study will be conducted remotely over 7 weeks.
The main questions it aims to answer are:
Researchers will compare an intervention snack bar to a control snack bar to see if the intervention improves hunger, gut microbiome, digestive symptoms and other health measures.
Participants will:
Diet, and snacking behaviour in particular, plays an important role in long-term health. Snacking now contributes substantially to daily energy intake in the UK and US: data from the ZOE PREDICT study show that 95% of adults snack at least once a day, with snacks accounting for around a quarter of daily energy intake (2.28 snacks/day). However, the average UK snack has a poor nutrient profile, high in refined carbohydrates, added sugars, and saturated fat, and low in fibre and micronutrients, a pattern linked to poorer cardiometabolic health. Despite public health guidance to consume at least 30g of fibre a day, UK adults consume an average of around 20g/day. However, the composition and timing of a snack are important determinants of its effects on hunger, energy, and other health markers.
This trial evaluates an intervention (2 x snack bars) against a control (2 x snack bars that reflect the average nutrient profile of snacks currently sold in the UK). Using a control snack bar means any effects observed can be attributed to the specific formulation of the intervention snack bar, rather than simply to a change in snacking habits or a reduction in overall snack consumption.
The primary aim of the study is to determine whether the intervention snack bars reduce subjective daily hunger over 5 weeks of daily use, compared with control snack bars representative of the average UK snack nutrient profile. The study will be conducted in 2 phases. In this phase (phase 2; chronic randomised controlled trial), 100 participants (50 per arm) will eat the intervention or control bars daily for 5 weeks. Secondary aims for this phase include the bar's effects on gut microbiome composition, gastrointestinal symptoms, bowel habits (frequency and consistency), subjective mood and energy, sleep quality, and anthropometric measures. The design allows the chronic effects of the intervention snack bars to be assessed when the bars are eaten regularly in place of habitual snack foods.
Zoe Global Limited is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Snack intervention (2x snack bars). To be eaten instead of regular snacks twice a day for 5 weeks.
Other: High-fibre plant-based snack bar
Control snack (2x snack bars). To be eaten instead of regular snacks twice a day for 5 weeks.
Other: Control snack bars
High-fibre plant-based snack bars.
Commercially available snack bars (UK); reflects the energy and macronutrient profile of a typical UK snack.
Daily hunger
Subjective hunger ratings, assessed using digital visual analogue scales (VAS; 0-100), with anchor points 0 = 'not at all hungry', 100 = 'extremely hungry'.
Time frame: 2-hourly intervals for 3 days, at baseline and week 5 of the intervention.
Microbiome composition
Relative abundance of selected microbiome species (those included in the ZOE microbiome-health ranks 2025 \& ZOE microbiome-diet ranks 2025), derived from metagenomic analysis of stool samples.
Time frame: Baseline, week 5 of the intervention.
Weight
Self-reported body weight (kg).
Time frame: Baseline, week 5 of the intervention.
Body mass index (BMI)
BMI (kg/m2) calculated from self-reported body weight (kg) and height (cm).
Time frame: Baseline, week 5 of the intervention.
Waist & Hip circumference
Self-reported waist and hip circumference (cm).
Time frame: Baseline, week 5 of the intervention.
Gastrointestinal symptoms
Subjective gastrointestinal symptoms, assessed using the Gastrointestinal Symptoms Ratings Scale. Participants rate symptoms on a 7-point scale ranging from 'no discomfort' to 'severe discomfort'.
Time frame: Baseline, week 5 of the intervention.
Stool frequency
Self-reported stool frequency (bowel movements per week) assessed via online questionnaire.
Time frame: Baseline, week 5 of the intervention.
Stool consistency
Self-reported stool consistency assessed via the Bristol Stool Form Scale. Participants rate their average stool consistency on a 7-point scale.
Time frame: Baseline, week 5 of the intervention.
Satiety
Subjective satiety ratings, assessed using digital visual analogue scales (VAS; 0-100), with anchor points 0 = 'not at all', 100 = 'extremely'.
Time frame: Baseline (3-days), week 5 of the intervention (3-days)
Subjective energy, mood & alertness
Subjective ratings of energy, mood and alertness, assessed using digital visual analogue scales (VAS; 0-100), with anchor points 0 = 'not at all', 100 = 'extremely'.
Time frame: Baseline (3-days), week 5 of the intervention (3-days)
Sleep
Self-reported sleep quality, assessed using the Pittsburgh Sleep Quality Index. Scores range from 0-6, with higher scores indicating poor sleep quality.
Time frame: Baseline, week 5 of the intervention.
Energy and nutrient intake
Energy (kcal) and nutrient intake (g/day; %EI), assessed using digital food log (myFood24).
Time frame: Baseline (3-days), week 5 of the intervention (3-days).
Treatment acceptability
Acceptability of intervention and control treatments, assessed via online questionnaire at endpoint.
Time frame: Week 5 of the intervention.
Microbiome composition
Relative abundance of selected microbiome species (those included in the ZOE microbiome-health ranks 2025 \& ZOE microbiome-diet ranks 2025), derived from metagenomic analysis of stool samples. Measured in a sub-group of participants (approx. n = 20) to determine whether there are detectable changes in the gut microbiome following a short term (2-3 weeks) dietary intervention.
Time frame: Week 3 of the intervention (midpoint)
Plan to share: Yes — To protect participant privacy, individual participant clinical data and any data that could be used to identify individuals will not be publicly available and cannot be deposited in public repositories. In line with journal requirements, data underlying the results in the publication may be made available to bona fide researchers for reproducibility of results. Proposals, researchers or institutions requesting data will be approved if they meet the standard criteria related to ethics, privacy and data protection regulations.
Supporting information: Study protocol, Analytic code
Time frame: Starting 6 months after publication.
Access criteria: The study data can be released to bona fide researchers by submitting a research proposal approved by a subpanel of our scientific advisory board which meets once per month with independent members to assess proposals. The data may be pseudo-anonymised or otherwise redacted to comply with the UK General Data Protection Regulation (GDPR). Researchers will be required to enter into a GDPR data sharing agreement before data may be released. Access request proposals should be sent to data.papers@joinzoe.com.
Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zoe Global Limited